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To the Editor: Kimmel and colleagues report that patients in the group receiving genotypeguided warfarin dosing did not show an improvement in the mean percentage of time in the therapeutic range. Using pharmacokineticpharmacodynamic data from our genotype-guided dose-initiation algorithm for warfarin, we found genotype-based dosing to be superior in patients who had atrial fibrillation as compared with patients who had venous thromboembolism, with the benefit increasing with increasing numbers of variant alleles. [1] [2] [3] We applied this model to simulate the data provided by Kimmel and colleagues and found no significant difference in INR response between dosing groups overall, as Kimmel and colleagues reported, but we did find that the genetics-based algorithm had clear benefits when the participants harbored 2 or more variant alleles (see Fig. 1 To the Editor: Two pharmacogenetic trials of warfarin therapy, European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) and Clarification of Optimal Anticoagulation through Genetics (COAG), reported by Pirmohamed and colleagues and Kimmel and colleagues, respectively, had contradictory messages. Could the results of a genotyping intervention differ according to the prevalence of a genotype that has the greatest effect on warfarin dosing? The prevalence of homozygotes, who required the most significant dosing changes, was 17% in EU-PACT versus 11% in the COAG trial for the VKORC1 variant and 3.4% in EU-PACT versus 1% in the COAG trial for the CYP2C9*2 and CYP2C9*3 variants. The possibility that genotype prevalence can attenuate outcomes was highlighted in the black cohort in the COAG trial, in which 75% of black patients and 25% of nonblack patients had no genotyped variants of CYP2C9 and VKORC1, and the prevalence of homozygotes for these genes in black and nonblack patients was less than 1% and 17%, respectively. Sample size in genotyping trials (e.g., Tailored No potential conflict of interest relevant to this letter was reported.
To the Editor: Kimmel and colleagues note that a genotype-guided dosing algorithm using CYP2C9*2, CYP2C9*3, and VKORC1 (−1639G→A) is statistically inferior to a clinical-dosing algorithm in patients of African descent. However, the singlenucleotide polymorphisms (SNPs) used in the study's pharmacogenetic dosing algorithm are known to occur at significantly lower frequencies in persons of African descent than in persons of European descent (Table 1) . [1] [2] [3] [4] The authors' ability to draw appropriate conclusions about the usefulness of genetics when determining dosages of warfarin for patients of African descent is thus very limited, and the benefits for this population have not been adequately tested. Physicians should not assume that self-reported race is an accurate proxy for the influence of genetic ancestry. 5 Rather, studies testing the usefulness of pharmacogenetics in a specific population should test variants with high frequency and measurable effect in that population. 
To the Editor: Results from the EU-PACT and COAG trials conflict with regard to the clinical usefulness of genotype-guided warfarin dosing. Whereas the EU-PACT trial showed a benefit with this approach in a homogeneous population in whom important variants are well defined, the COAG study failed to show a benefit in a racially diverse population. Genotyping for both trials was limited to VKORC1 and CYP2C9*2 and CYP2C9*3, which is an appropriate selection for a population of European descent but not necessarily for non-European populations. We and others have shown distinct associations with genetic warfarin dosing in patients of African descent, who comprised nearly 30% of the COAG population. [1] [2] [3] Approximately 20% of persons of African descent carry the allele CYP2C9*5, CYP2C9*6, CYP2C9*8, or CYP2C9*11, and 44% carry an A allele for SNP rs12777823, all of which portend lower dose requirements. 2, 3 The COAG trial would have misclassified these genotypes as variant, which probably explains why more African patients received an overdose when their regimen was determined with the genotype-guided strategy. We contend that until race-specific variants are accounted for in pharmacogenetic algorithms applied to minorities, the benefits of genotype-guided dosing in these patients will not be sufficiently addressed. Dr. Kimmel and Colleagues Reply: We appreciate the comments of Koller and colleagues and Schwarz and colleagues and have performed the suggested analyses. There were no significant differences between the dosing strategies in the primary outcome when stratified by age (<65 years vs. ≥65 years; P = 0.24 for the interaction) or by primary indication (deep-vein thrombosis or pulmonary embolism vs. other; P = 0.16 for the interaction). Similar results were obtained when the data were stratified by number of variants (≥2 vs. 0 or 1) (P = 0.92 for the interaction in the entire study population; P = 0.51 for the interaction in the population of African descent; and P = 0.28 for the interaction in the population not of African descent). We do not have pharmacokinetic data. Pereira and colleagues suggest that the results of a genotyping intervention could differ according to the prevalence of the genotype that has the greatest effect on warfarin dosing. We tested this hypothesis; it is not supported by the data (see Table 2 in our article). Furthermore, it should be noted that patients with no variants or with more than one variant in either CYP2C9 or VKORC1 (for whom pharmacogenetic dosing algorithms predict a higher and lower dose, respectively, than the clinical algorithms) would be expected to benefit the most. 1 In its sample size calculations, the COAG trial considered the presence of genetic variants most likely to have an effect on dosing and powered the trial to examine the group most likely to benefit from genotyping (those with predicted dose difference of ≥1 mg or more per day between the pharmacogenetic and clinical algorithms). 2 We agree with Daneshjou and colleagues and with Cavallari and colleagues that patients of African descent might benefit from algorithms that use additional genetic variants. However, we note that there were 701 patients in the trial who were not of African descent, a sample size larger than that of either of the EU-PACT studies, and there was no significant benefit of pharmacogenetics in this group, despite the excellent dose prediction when the dosing algorithm variants were used. Thus, whether better prediction for initial dosing in patients of African descent will lead to better anticoagulation control remains an untested hypothesis. For now, the best available evidence is that the use of existing genetic variants approved by the Food and Drug Administration for the prediction of dose may worsen 30-day anticoagulation control in this population. We also agree that self-reported race is not necessarily an accurate proxy for the influence of genetic ancestry. However, clinical use of warfarin pharmacogenetics relies on self-reported race. In comparing trials, we believe that the most important factor is the hypothesis that each trial tested. The COAG trial of warfarin and the EU-PACT trial of acenocoumarol and phenprocoumon tested the hypothesis that genetic information would improve anticoagulation control when added to clinical information. Neither trial showed a benefit in the primary outcome. In contrast, the EU-PACT trial of warfarin tested a different hypothesis: that an algorithm using both genetic and clinical information would improve anticoagulation control as compared with a strategy that was not tailored to clinical factors other than age. 
Dr. Pirmohamed and Colleagues Reply: We agree with Koller and colleagues that exposure is more important than dosage. We therefore incorporated CYP2C9 genetic status into our algorithms from the first day of dosing, since this is the main determinant of warfarin exposure. In the trial by Kimmel and colleagues, the first dose of warfarin was not informed by genotyping in the majority of the patients, which may be one reason for the differences in outcomes. As evidenced by the older age of the patients in our study, there was a higher proportion with atrial fibrillation than in the COAG trial, and the effects of age and interacting medications were taken into account by the algorithms. Given the pragmatic nature of our trial, we did not obtain blood samples for pharmacokinetic analysis.
Our further analyses, to be published separately, have indicated that the greatest effect of the genotype-guided dosing algorithm on the percentage of time in the therapeutic range was in patients with variant alleles. Thus, we would agree with Pereira and colleagues that the differences between the two trials in variant genotypes may have contributed to the divergent results. The differences in algorithmic strategies may also have been a factor, since a loading dose of warfarin accelerated the attainment of a steady state, and therefore a change in the INR, on day 4, when the same dose revision algorithm was used in the two trials.
Another reason for the difference between the two trials relates to the differences in the homogeneity of the populations. Thus, we would agree with Cavallari and colleagues that patients in the COAG trial who were of African descent may have benefited from algorithms that used additional genetic variants. It has also been suggested that in the EU-PACT trial, genotypingguided dosing was associated with a greater time in the therapeutic range because genotype-guided dosing was compared with a standard fixed-dose regimen, whereas in the COAG trial a clinicaldosing algorithm was used as a comparator. However, the time in the therapeutic range in our groups was either equivalent to or superior to that reported for the COAG trial at 4 weeks, even when the patients in the COAG trial who were not of African descent were used for comparison. The difference in blinding (single vs. double) is unlikely to have accounted for the differences in results, since in the EU-PACT trial we used an objective biomarker (i.e., INR) as the end point, and dose changes were handled in both groups after day 5 by entering the latest INR into computerized dosing software programs routinely used in our anticoagulant clinics. Since publication of their article, the authors report no further potential conflict of interest.
Dr. Maitland-van der Zee and Colleagues Reply: Koller and colleagues asked whether patients in the EU-PACT trial were stratified by age (Table 1) . Among patients who were younger than 75 years of age (334 patients), the difference in the percentage of time in the INR range between the groups that did or did not undergo genotyping was 5.1 percentage points during the 12 weeks after the initiation of therapy (P = 0.05) and 7.5 percentage points during the first 4 weeks (P = 0.01). Among the patients who were 75 years of age or older (150 patients), the genotyped group spent less time in the INR range during the 12-week period (difference, 7.1 percentage points; P = 0.06), and there was no significant difference in the time spent during the first 4 weeks (difference, 0.4 percentage points; P = 0.93). Therefore, it seems that the genetic information is more important for younger patients.
In our trial, it was not possible to study the effect of race because almost all patients were white. Finally, because we had INR measurements for the dosing of coumarin, we did not consider it useful to gather pharmacokinetic data. The New England Journal of Medicine
